menu
    • menu
    [{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurogastrx \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metopimazine Mesylate","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogastrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurogastrx

    Menu

    Neurogastrx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Metopimazine Mesylate,Semaglutide

    Therapeutic Area : Neurology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Neurogastrx Shows Positive Data for NG101 in GLP-1 Related Nausea

    Details : NG101 is an oral, peripherally restricted dopamine D2 receptor antagonist, being investigated for nausea and vomiting side effects caused by GLP-1 agonist medication.

    Product Name : NG101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 16, 2024

    Lead Product(s) : Metopimazine Mesylate,Semaglutide

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Metopimazine Mesylate

    Therapeutic Area : Gastroenterology

    Study Phase : Phase II

    Sponsor : Vivo Capital

    Deal Size : $60 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Neurogastrx Secures $60 Million Series B Financing to Advance Gastrointestinal Therapies

    Details : Company will use the proceeds to advance its GI therapies including fexuprazan for the treatment of erosive esophagitis and NG101 (metopimazine mesylate) for gastroparesis.

    Product Name : NG101

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 26, 2021

    Lead Product(s) : Metopimazine Mesylate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase II

    Sponsor : Vivo Capital

    Deal Size : $60 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fexuprazan

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Vivo Capital

    Deal Size : $60.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline for ...

    Details : Proceeds from the financing will be used to advance the company’s pipeline of GI therapies, DWP14012, for serious conditions that impact millions of people yet are not effectively treated.

    Product Name : DWP14012

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 26, 2021

    Lead Product(s) : Fexuprazan

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Vivo Capital

    Deal Size : $60.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Neurogastrx

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fexuprazan

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Daewoong Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Relat...

    Details : Daewoong Pharmaceutical will take a significant equity stake in Neurogastrx, ramping to 13.5% ownership upon an initial public offering (IPO). Neurogastrx has the exclusive right to develop and commercialize fexuprazan in the U.S. and Canada.

    Product Name : DWP14012

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 06, 2021

    Lead Product(s) : Fexuprazan

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Daewoong Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth